Accelr8 Posts Flat Revenues, Narrowed Loss in Fiscal Q1; Sheds No Light on BACcelr8r Availability | GenomeWeb
NEW YORK (GenomeWeb News) — Accelr8 Technology yesterday said fiscal first-quarter revenues were unchanged though net loss decreased 30 percent.  
 
Total receipts for the three months ended Oct. 31 were flat at $86,000.
 
Accelr8 said net losses declined to $539,000 from $772,000 in the year-ago period.
 
The company attributed the decline to reduced research expenses for its BACcelr8r bacterial-analysis system, which is being prepared for clinical trials.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.